Cue Biopharma, Inc.

CUE Healthcare Biotechnology

Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024. In the quarter to June 2026, revenue grew 166.7%, EPS fell 793.2% and free cash flow fell 742.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

16.71 1.96 −10.50%
Market cap
$135.6M
P/E
0.0×
Fwd P/E
−4.4×
Dividend yield
—
F-score
5/9
Altman Z
−11.88
Beneish M
−0.40
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(1,603.48%) (138.52%) (121.11%) (195.19%)

+8 more TTM periods

Piotroski F-Score
3 4 5 3
ROA
(459.60%) (73.49%) (71.51%) (98.58%)
ROIC
0.00% (294.07%) 0.00% 0.00%
Return on Tangible Assets
(2,899.43%) (101.21%) (112.10%) (355.43%)
Average Days of Receivables
52.12 59.67 73.70 19.90
Free Cash Flow per Share
(7.91) (5.11) (6.92) (8.87)
Free Cash Flow
(50.13) (24.56) (21.82) (29.80)
Capital Expenditures
(0.08) (0.11) (0.14) (0.16)
Other line items
Cash ROIC
(254.14%) (62.91%) (39.93%) (84.38%)
Accounts Receivable Turnover
12.74 10.40 6.32 6.36
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
205.00% 110.27% 137.42% 399.94%
Selling, General and Administrative Expense of Revenue
156.98% 49.56% 59.14% 236.79%
Share Based Compensation of Revenue
69.13% 10.55% 17.27% 80.23%
Interest Coverage
(511.22) (84.15) (74.38) (95.41)
Operating CF/Net income
0.31 1.25 0.82 0.79
Depreciation/Fixed assets
4.58 4.19 3.25 0.76
Capex/Depreciation
(0.07) (0.09) (0.17) (0.68)
Revenue per Share
5.94 6.81 8.71 2.11
Operating CF per Share
(7.89) (5.09) (6.87) (8.82)
Capex per Share
(0.01) (0.02) (0.04) (0.05)
Capex to Sales
0.00 0.00 0.01 0.02

Fold the line items

Columns are period end dates